OBJECTIVE: There are no data regarding the long-term prognostic value of single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in obese patients. The aim of this study was to examine the value of stress (99m)Tc-tetrofosmin MPI findings for the prediction of very long-term outcome in obese patients. METHODS: The study population consisted of 261 patients with a body mass index ≥30 kg/m(2) who underwent exercise or pharmacological stress (99m)Tc-tetrofosmin MPI for the assessment of known or suspected coronary artery disease. Endpoints during follow-up were all-cause mortality, cardiac death, nonfatal infarction, and coronary revascularization. Kaplan-Meier survival cures were constructed and univariate and multivariate analyses were performed to identify predictors of very long-term outcome. RESULTS: The mean age was 59 ± 10 years, 42% of the patients was male, and the body mass index was on average 37 ± 7 kg/m(2). MPI findings were normal in 109 patients (42%). Myocardial perfusion abnormalities were fixed in 62 patients (24%) and reversible in 90 patients (34%). During a median 12-year follow-up, 91 (35%) patients died, and 27 (10%) had a nonfatal myocardial infarction. Survival curves were compared using the log-rank test at subsequent follow-up durations. Obese patients with a normal stress (99m)Tc-tetrofosmin study had a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test was performed. CONCLUSION: Stress (99m)Tc-tetrofosmin MPI provides valuable prognostic information for the prediction of outcome in obese patients. Obese patients with a normal stress (99m)Tc-tetrofosmin study have a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test is performed.
OBJECTIVE: There are no data regarding the long-term prognostic value of single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in obesepatients. The aim of this study was to examine the value of stress (99m)Tc-tetrofosmin MPI findings for the prediction of very long-term outcome in obesepatients. METHODS: The study population consisted of 261 patients with a body mass index ≥30 kg/m(2) who underwent exercise or pharmacological stress (99m)Tc-tetrofosmin MPI for the assessment of known or suspected coronary artery disease. Endpoints during follow-up were all-cause mortality, cardiac death, nonfatal infarction, and coronary revascularization. Kaplan-Meier survival cures were constructed and univariate and multivariate analyses were performed to identify predictors of very long-term outcome. RESULTS: The mean age was 59 ± 10 years, 42% of the patients was male, and the body mass index was on average 37 ± 7 kg/m(2). MPI findings were normal in 109 patients (42%). Myocardial perfusion abnormalities were fixed in 62 patients (24%) and reversible in 90 patients (34%). During a median 12-year follow-up, 91 (35%) patients died, and 27 (10%) had a nonfatal myocardial infarction. Survival curves were compared using the log-rank test at subsequent follow-up durations. Obesepatients with a normal stress (99m)Tc-tetrofosmin study had a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test was performed. CONCLUSION: Stress (99m)Tc-tetrofosmin MPI provides valuable prognostic information for the prediction of outcome in obesepatients. Obesepatients with a normal stress (99m)Tc-tetrofosmin study have a significantly better prognosis as compared with those with an abnormal study, up to 6 years after the test is performed.
Authors: L J Shaw; R Hachamovitch; D S Berman; T H Marwick; M S Lauer; G V Heller; A E Iskandrian; K L Kesler; M I Travin; H C Lewin; R C Hendel; S Borges-Neto; D D Miller Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: Rory Hachamovitch; Sean Hayes; John D Friedman; Ishac Cohen; Leslee J Shaw; Guido Germano; Daniel S Berman Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: A F L Schinkel; J J Bax; M L Geleijnse; E Boersma; A Elhendy; J R T C Roelandt; D Poldermans Journal: Eur Heart J Date: 2003-05 Impact factor: 29.983
Authors: Abdou Elhendy; Arend F L Schinkel; Ron T van Domburg; Jeroen J Bax; Roelf Valkema; Elena Biagini; Don Poldermans Journal: J Nucl Med Date: 2006-08 Impact factor: 10.057
Authors: Abel Romero-Corral; Victor M Montori; Virend K Somers; Josef Korinek; Randal J Thomas; Thomas G Allison; Farouk Mookadam; Francisco Lopez-Jimenez Journal: Lancet Date: 2006-08-19 Impact factor: 79.321
Authors: Paul Poirier; Thomas D Giles; George A Bray; Yuling Hong; Judith S Stern; F Xavier Pi-Sunyer; Robert H Eckel Journal: Circulation Date: 2005-12-27 Impact factor: 29.690
Authors: Leslee J Shaw; Robert Hendel; Salvador Borges-Neto; Michael S Lauer; Naomi Alazraki; Joy Burnette; Elizabeth Krawczynska; Manuel Cerqueira; Jamshid Maddahi Journal: J Nucl Med Date: 2003-02 Impact factor: 10.057
Authors: Tiffany M Powell-Wiley; Paul Poirier; Lora E Burke; Jean-Pierre Després; Penny Gordon-Larsen; Carl J Lavie; Scott A Lear; Chiadi E Ndumele; Ian J Neeland; Prashanthan Sanders; Marie-Pierre St-Onge Journal: Circulation Date: 2021-04-22 Impact factor: 29.690
Authors: Eyal Klein; Robert J H Miller; Tali Sharir; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Yuka Otaki; Heidi Gransar; Joanna X Liang; Damini Dey; Daniel S Berman; Piotr J Slomka Journal: J Nucl Cardiol Date: 2020-09-14 Impact factor: 5.952